Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis

American Journal of Gastroenterology

Volumn 93, Issue 9, 1998, Pages 1498-1504

  Lindor, Keith D ^a   Lacerda, M A ^b   Jorgensen, R A ^b   DeSotel, C K ^b   Batta, A K ^b   Salen, G ^b   Dickson, E R ^b   Rossi, S S ^b   Hofmann, A F ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILE ACID; BILIRUBIN; URSODEOXYCHOLIC ACID;

ARTICLE; BILE ACID BLOOD LEVEL; BILE COMPOSITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BILE; BILE ACIDS AND SALTS; CHENODEOXYCHOLIC ACID; CHOLAGOGUES AND CHOLERETICS; CHOLIC ACIDS; DOUBLE-BLIND METHOD; HUMANS; LIVER CIRRHOSIS, BILIARY; PATIENT COMPLIANCE; URSODEOXYCHOLIC ACID;

EID: 0032173265     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1998.00470.x     Document Type: Article

References (38)

1. 1. Poupon RE, Poupon R, Balkau B, and the UDCA-PSC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-7.
2. 2. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterol 1994;106: 1284-90.
3. 3. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatol 1994;19:1149-56.
4. 4. Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatol 1995;22:759-66.
5. 5. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of French, American, and Canadian randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
6. 6. Podda M, Ghezzi C, Battezzati PM, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989;34: 59S-65S.
7. 7. Jazrawi RP, DeCaestecker JS, Goddin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid. Gastroenterol 1994;106:134-42.
8. 8. Calmus Y, Gane P, Rouger P, et al. Hepatic expression of class I and Class II major histocompatibility complex molecules in primary biliary cirrhosis: Effects of ursodeoxycholic acid. Hepatol 1990;11:12-5.
9. 9. Yoshikawa M, Tsujii T, Matsumura K, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatol 1992; 16:358-64.
10. 10. Rossi SS, Converse JL, Hofmann AF. High pressure liquid chromatographic analysis of conjugated bile acids in human bile: Simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res 1987;28:589-95.
11. 11. Fisher RL, Hofmann AF, Converse JL, et al. Lack of relationship between hepatotoxicity and lithocholic acid sulfation during chenodiol therapy in the National Cooperative Gallstone Study. Hepatol 1991; 14:454-63.
12. 12. Batta AK, Arora R, Salen G, et al. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gasliquid chromatography-mass spectrometry: Effect of ursodeoxycholic acid treatment. J Lipid Res 1989;30:1953-62.
13. 13. Batta AK, Shefer S, Batta M, et al. Effect of chenodeoxycholic acid on biliary and urinary bile acids and bile alcohols in cerebrotendinous xanthomatosis: Monitoring by high performance liquid chromatography. J Lipid Res 1985;26:690-8.
14. 14. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: Model for decision making. Hepatol 1989;10:1-7.
15. 15. Batta AK, Salen G, Mirchandani R, et al. Effect of long-term treatment with Ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 1993;88:691-700.
16. 16. Crosignani A, Podda M, Battezati PM. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatol 1991;14:1000-7.
17. 17. Mazzella G, Parini P, Bazzoli F, et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993;38:896-902.
18. 18. Fischer S, Neubrand M, Paumgartner G. Biotransformation of orally administered ursodeoxycholic acid in man as observed in gallbladder bile, serum, and urine. Eur J Clin Invest 1993;23:28-36.
19. 19. Steihl A, Rudolph G, Raedsch R, et al. Ursodeoxycholic acid induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatol 1990;12:492-7.
20. 20. Van de Meeberg PC, Wolfhagen FHJ, VanBerge Henegouwen GP, et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: Biliary enrichment and biochemical response. J Hepatol 1996; 25:887-94.
21. 21. Poupon RE, Chretien Y, Poupon R. Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy. Hepatol 1993;17: 599-604.
22. 22. Chretien Y, Poupon R, Gherardt MF. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic acid treatment. Gut 1989;30:1110-5.
23. 23. Hofmann AF. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994;29(suppl 204):1-15.
24. 24. Allan RN, Thistle JL, Hofmann AF. Lithocholate metabolism during chemotherapy for gallstone dissolution. II. Absorption and sulphation. Gut 1976;17:413-9.
25. 25. Fedorowski T, Salen G, Calallilo A, et al. Metabolism of ursodeoxycholic acid in man. Gastroenterol 1977;73:1131-7.
26. 26. Hirano S, Masuda N, Oda H. In vitro transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal flor, with particular reference to the mutual conversion between the two bile acids. J Lipid Res 1981;22:735-43.
27. 27. Raedsch R, Lauterburg BH, Hofmann AF. Altered bile acid metabolism in primary biliary cirrhosis. Dig Dis Sci 1981;26:394-401.
28. 28. Pomare EW, Low-Beer TS. Measurement and validation of human bile salt pool size and synthesis. Clinica Chimica Acta 1974;57:239-48.
29. 14C-glycine as a test of hepatocellular disease. Gut 1977;18:697-702.
30. 30. LaRusso NF, Hoffman NE, Korman MG, et al. Determinants of fasting and postprandial serum bile acid levels in healthy man. Am J Dig Dis 1978;23:385-91.
31. 31. Beckett GJ, Douglas JG, Finlayson ND, et al. Differential timing of plasma chenodeoxycholate and cholate: Its variability and implications. Digestion 1981;22:248-54.
32. 32. Schalm SW, LaRusso NF, Hofmann AF, et al. Diurnal serum levels in primary conjugated bile acids. Assessment by specific radioimmuno-assays for conjugates of cholic and chenodeoxycholic acid. Gut 1978; 19:1006-14.
33. 33. VanderWerf SD, vanBerge Henegouwen GP, vandenBroek W. Estimation of bile acid pool sizes from their spillover into systemic blood. J Lipid Res 1985;26:168-74.
34. 34. Muraca M, Vilei MT, Miconi L, et al. A simple method for determination of lipid composition of human bile. J Lipid Res 1991;32:371-4.
35. 35. Bazzoli F, Fromm H, Roda A, et al. Value of serum determinations for prediction of increased ursodeoxycholic and chenodeoxycholic levels in bile. Dig Dis Sci 1985;30:650-4.
36. 36. Bazzoli F, Roda A, Fromm H, et al. Relationship between serum and biliary bile acids as an indicator of chenodeoxycholic and ursodeoxycholic acid-induced hepatotoxicity in the rhesus monkey. Dig Dis Sci 1982;27:417-24.
37. 37. Guldutuna S, Leuschner M, Wunderlich N, et al. Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function. Eur J Clin Pharma 1993;45:221-5.
38. 38. Jorgensen RA, Dickson ER, Lindor KD. Characteristics of patients with primary biliary cirrhosis having a complete biochemical response to Ursodiol. Gut 1995;36:935-8.